New Drug Application for Accrufer® in South... | 28-May-2024 | 07:00 | RNS |
Audited results for the year ended 31 Dec 2023 | 10-May-2024 | 15:30 | RNS |
Business Update for Q1 2024 | 30-Apr-2024 | 07:00 | RNS |
Notice of Results | 16-Apr-2024 | 07:00 | RNS |
Unaudited Full Year Trading Update | 21-Feb-2024 | 07:00 | RNS |
Appointment of new Chief Financial Officer | 09-Jan-2024 | 07:00 | RNS |
Q3 2023 U.S. Commercial Highlights | 07-Dec-2023 | 07:00 | RNS |
PDMR Transaction Notification | 27-Nov-2023 | 17:24 | RNS |
Chief Financial Officer Transition | 12-Oct-2023 | 07:00 | RNS |
Result of REX Retail Offer | 03-Oct-2023 | 15:00 | RNS |
Block listing Interim Return | 03-Oct-2023 | 07:00 | RNS |
Completion of SWK Financing | 03-Oct-2023 | 07:00 | RNS |
Successful completion of US$6.1m Equity Fundraise | 28-Sep-2023 | 12:50 | RNS |
REX Retail Offer | 28-Sep-2023 | 07:02 | RNS |
$20m secured debt facility &proposed equity raise | 28-Sep-2023 | 07:01 | RNS |
Currency | UK Pounds |
Share Price | 2.05p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 12.50 |
52 Week Low | 1.23 |
Volume | 690,953 |
Shares Issued | 782.06m |
Market Cap | £16.03m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 0 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:18 | 50,000 @ 2.01p |
15:31 | 18,000 @ 2.10p |
14:55 | 1,000 @ 2.00p |
14:55 | 8,000 @ 2.01p |
12:16 | 32,000 @ 2.10p |
You are here: research